NeuroThera and Clearmind File Patent for Novel Depression Therapy

NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced that its collaboration with Clearmind Medicine Inc. has resulted in a patent application filed with the Intellectual Property Department in Hong Kong, China. The application covers an innovative combination therapy designed to treat major depressive disorder, a condition affecting over 332 million people globally according to the World Health Organization article titled "Depressive Disorder (Depression)" published in August 2025.

The therapy combines Clearmind's proprietary 5-methoxy-2-aminoindane with Palmitoylethanolamide sourced by NeuroThera. This MEAI-PEA synergy represents a non-hallucinogenic neuroplastogen option for combating depression, potentially providing a more accessible, safer, and affordable alternative to existing antidepressants including Selective Serotonin Reuptake Inhibitors and other conventional treatments. The patent filing underscores the promise of this approach at a time when novel treatments for major depressive disorder are in high demand.

Clearmind's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents, with shares listed for trading on Nasdaq under the symbol "CMND." For further information about Clearmind, visit https://www.clearmindmedicine.com. The companies face various risks and uncertainties in developing this therapy, including the early stage of development, potential regulatory hurdles, and intellectual property challenges. Additional information about these risks is available in the Company's public filings on https://www.sedarplus.ca.

Forward-looking statements in the announcement emphasize the potential therapeutic benefits and market advantages of the MEAI-PEA combination, though these are not guarantees of future performance. The collaboration between NeuroThera and Clearmind continues to advance toward commercialization, with both companies working to address widespread and underserved health problems through innovative pharmaceutical approaches. The original release can be viewed on https://www.newmediawire.com.